ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Scott Rowley on Allogeneic Stem Cell Transplant

Scott Rowley, MD
Published: Wednesday, Jan 21, 2015



Scott Rowley, MD, the Chief of John Theurer Cancer Center’s Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

Many allogeneic transplant candidates have resistant disease or comorbidities​ due to previous treatments. This has resulted in a push for creating reduced or less toxic regimens.

The biggest challenge in allogeneic transplant is post-transplant relapse. A primary area of focus in the transplant community is to find novel agents or regimens to reduce risk of relapse, says Rowley.


Scott Rowley, MD, the Chief of John Theurer Cancer Center’s Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

Many allogeneic transplant candidates have resistant disease or comorbidities​ due to previous treatments. This has resulted in a push for creating reduced or less toxic regimens.

The biggest challenge in allogeneic transplant is post-transplant relapse. A primary area of focus in the transplant community is to find novel agents or regimens to reduce risk of relapse, says Rowley.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x